Spinocerebellar Ataxia 1 (SCA1)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter provides an overview of Spinocerebellar ataxia type 1 (SCAl). SCAl is an autosomal dominant neurodegenerative disease typically with mid-life onset characterized by motor symptoms in the absence of cognitive deficits. SCAl is a member of an intriguing group of neurodegnerative disorders known as the polyglutamine diseases. At the present, nine diseases are shown to result from expansion of CAG repeats coding for polyglutamine tracts in the respective proteins. These disorders include spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), spinocerebellar ataxias, and dentatorubropallidoluysian atrophy (DRPLA).Expansion of the polyglutamine tract in the SCAl encoded protein, ataxin-1, results in an alteration in its folding. A key aspect of SCAl pathogenesis is localization of mutant ataxin-1 to the nucleus.

Original languageEnglish (US)
Title of host publicationGenetics of Movement Disorders
PublisherElsevier Inc.
Pages35-43
Number of pages9
ISBN (Print)9780125666527
DOIs
StatePublished - Jan 1 2003

Fingerprint

Spinocerebellar Ataxias
Atrophic Muscular Disorders
Neurodegenerative diseases
Huntington Disease
Neurodegenerative Diseases
Atrophy
polyglutamine
Proteins
Ataxin-1

Cite this

Orr, H. T. (2003). Spinocerebellar Ataxia 1 (SCA1). In Genetics of Movement Disorders (pp. 35-43). Elsevier Inc.. https://doi.org/10.1016/B978-012566652-7/50005-8

Spinocerebellar Ataxia 1 (SCA1). / Orr, Harry T.

Genetics of Movement Disorders. Elsevier Inc., 2003. p. 35-43.

Research output: Chapter in Book/Report/Conference proceedingChapter

Orr, HT 2003, Spinocerebellar Ataxia 1 (SCA1). in Genetics of Movement Disorders. Elsevier Inc., pp. 35-43. https://doi.org/10.1016/B978-012566652-7/50005-8
Orr HT. Spinocerebellar Ataxia 1 (SCA1). In Genetics of Movement Disorders. Elsevier Inc. 2003. p. 35-43 https://doi.org/10.1016/B978-012566652-7/50005-8
Orr, Harry T. / Spinocerebellar Ataxia 1 (SCA1). Genetics of Movement Disorders. Elsevier Inc., 2003. pp. 35-43
@inbook{095454f0e1834609a072a2460e2ecda7,
title = "Spinocerebellar Ataxia 1 (SCA1)",
abstract = "This chapter provides an overview of Spinocerebellar ataxia type 1 (SCAl). SCAl is an autosomal dominant neurodegenerative disease typically with mid-life onset characterized by motor symptoms in the absence of cognitive deficits. SCAl is a member of an intriguing group of neurodegnerative disorders known as the polyglutamine diseases. At the present, nine diseases are shown to result from expansion of CAG repeats coding for polyglutamine tracts in the respective proteins. These disorders include spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), spinocerebellar ataxias, and dentatorubropallidoluysian atrophy (DRPLA).Expansion of the polyglutamine tract in the SCAl encoded protein, ataxin-1, results in an alteration in its folding. A key aspect of SCAl pathogenesis is localization of mutant ataxin-1 to the nucleus.",
author = "Orr, {Harry T}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/B978-012566652-7/50005-8",
language = "English (US)",
isbn = "9780125666527",
pages = "35--43",
booktitle = "Genetics of Movement Disorders",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Spinocerebellar Ataxia 1 (SCA1)

AU - Orr, Harry T

PY - 2003/1/1

Y1 - 2003/1/1

N2 - This chapter provides an overview of Spinocerebellar ataxia type 1 (SCAl). SCAl is an autosomal dominant neurodegenerative disease typically with mid-life onset characterized by motor symptoms in the absence of cognitive deficits. SCAl is a member of an intriguing group of neurodegnerative disorders known as the polyglutamine diseases. At the present, nine diseases are shown to result from expansion of CAG repeats coding for polyglutamine tracts in the respective proteins. These disorders include spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), spinocerebellar ataxias, and dentatorubropallidoluysian atrophy (DRPLA).Expansion of the polyglutamine tract in the SCAl encoded protein, ataxin-1, results in an alteration in its folding. A key aspect of SCAl pathogenesis is localization of mutant ataxin-1 to the nucleus.

AB - This chapter provides an overview of Spinocerebellar ataxia type 1 (SCAl). SCAl is an autosomal dominant neurodegenerative disease typically with mid-life onset characterized by motor symptoms in the absence of cognitive deficits. SCAl is a member of an intriguing group of neurodegnerative disorders known as the polyglutamine diseases. At the present, nine diseases are shown to result from expansion of CAG repeats coding for polyglutamine tracts in the respective proteins. These disorders include spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), spinocerebellar ataxias, and dentatorubropallidoluysian atrophy (DRPLA).Expansion of the polyglutamine tract in the SCAl encoded protein, ataxin-1, results in an alteration in its folding. A key aspect of SCAl pathogenesis is localization of mutant ataxin-1 to the nucleus.

UR - http://www.scopus.com/inward/record.url?scp=84902399441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902399441&partnerID=8YFLogxK

U2 - 10.1016/B978-012566652-7/50005-8

DO - 10.1016/B978-012566652-7/50005-8

M3 - Chapter

SN - 9780125666527

SP - 35

EP - 43

BT - Genetics of Movement Disorders

PB - Elsevier Inc.

ER -